Plain-English translation of NCT07264517 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial studied , a new eye drop medication designed to treat moderate to severe dry eye disease. Participants received either the active medication or a placebo (inactive) drop twice a day—once in the morning and once in the evening—while researchers tracked whether the medication was safe, well-tolerated, and effective at reducing symptoms and improving eye surface health.
Dry eye disease affects millions of people and can cause significant discomfort and vision problems. Researchers wanted to determine whether this new medication could offer patients a better treatment option than currently available alternatives.
Participants visited the clinic multiple times during a screening period and then were randomly assigned to receive either the active medication or placebo drops to use twice daily at home. Throughout the study, they had follow-up appointments where researchers examined their eyes, measured tear production, checked for corneal damage under magnification, and asked about symptom improvement—all to determine whether the new treatment was safe and effective.
AI-generated summary from trial data · Jun 19, 2026 · Not medical advice
United States